[EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF [FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION POUR TRAITER OU PRÉVENIR LA GRIPPE, OU POUR ATTÉNUER SES SYMPTÔMES
Nachbargruppenbeteiligung bei der Bildung von kondensierten Azinen. Über die Darstellung von Derivaten von Pyrazolo(3,4-b)pyrazin, Isoxazolo(4,5-b)pyrazin und Isothiazolo(5,4-b)pyridin. (Heterocyclen, 210. Mitt.)
[EN] 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS<br/>[FR] DÉRIVÉS DE 3-(2- (HÉTÉROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMÉTHYL) -1,2,4-OXADIAZOLE UTILISÉS EN TANT QU'INHIBITEURS DE HDAC6
申请人:ORYZON GENOMICS SA
公开号:WO2020245381A1
公开(公告)日:2020-12-10
The invention relates to compounds as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.
[EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION POUR TRAITER OU PRÉVENIR LA GRIPPE, OU POUR ATTÉNUER SES SYMPTÔMES
申请人:SAVIRA PHARMACEUTICALS GMBH
公开号:WO2017133667A1
公开(公告)日:2017-08-10
Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.
Redefining the Synthetic Logic of Medicinal Chemistry. Photoredox-Catalyzed Reactions as a General Tool for Aliphatic Core Functionalization
作者:David F. Fernández、María González-Esguevillas、Sebastian Keess、Felix Schäfer、Jens Mohr、Andre Shavnya、Thomas Knauber、David C. Blakemore、David W. C. MacMillan
DOI:10.1021/acs.orglett.3c00994
日期:2024.4.12
C(sp3)-rich aliphatic motifs in drug molecules are strongly associated with clinical success. Historically, the availability of compound libraries based on C(sp3)-rich cores has been limited due to the challenging direct functionalization of aliphatic rings. Instead, most small molecule drug-like libraries are diversified around central aromatic rings. Herein, we present a general approach to the synthesis